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ABSTRACT
Multiple sclerosis (MS) is an autoimmune disease characterized by the 
dysregulated immune response including innate and adaptive immune responses. 
Increasing evidence has proven the importance of epigenetic modification in 
the progression of MS. Recent studies revealed that low-dose decitabine (Dec, 
5-Aza-2’-deoxycytidine), which incorporates into replicating DNA and inhibits 
DNA methylation, could prevent experimental autoimmune encephalomyelitis 
(EAE) development by increasing the number of regulatory T cells (Tregs). 
Here, we showed that higher-dose decitabine relative to previous studies could 
also distinctly protect mice from EAE and allogeneic cardiac transplantation. 
Mechanistic studies revealed decitabine suppressed innate responses in EAE mice 
through inhibiting the activation of microglia and monocyte-derived macrophages 
that contributed to reduce the severity of EAE. Furthermore, differentiation 
of naïve CD4+ T cells into Th1 and Th17 cells was significantly suppressed by 
decitabine in vivo and in vitro. Though in vitro studies showed decitabine could 
induce Treg differentiation, there was no obvious change in the percentage of 
Tregs in Dec-treated EAE mice. Most importantly, we found that T cell proliferation 
was potently inhibited in vivo and in vitro by higher-dose decitabine through 
increased gene expression of the DNA dioxygenase TET2 which facilitated the 
expression of several cell cycle inhibitors. Collectively, our study provides novel 
mechanistic insights of using the epigenetic modifying agents in the management 
of both allo- and auto-immune responses.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory, 
demyelinating disease of the central nervous system 
(CNS), affecting approximately 2.5 million individuals 
worldwide. It manifests as neurological deficits that 
frequently exhibit a relapsing-remitting pattern, and can 
either resolve completely or leave residual deficits. A 
complicated inflammatory cascade involving both the 
innate and adaptive immune responses is believed to 
initiate and control the disease progression [1, 2]. So far 
there is no effective therapeutic means in the management 
of MS. Currently available disease-modifying drugs like 
interferon-β (IFN-β), glatiramer acetate, fingolimod, etc, 
have either limited efficacy or serious side effects [1, 
3]. Thus, there is still an urgent need to develop more 
effective and safer drugs for the treatment of MS.
Due to the similarity of key pathological features 
of MS and the well-established mouse model of 
experimental autoimmune encephalomyelitis (EAE), such 
as demyelination, inflammation, axonal loss and gliosis, 
EAE has become the most commonly used experimental 
model for investigating the mechanisms of MS, as well as 
for therapeutic development [4]. It is widely believed that 
autoreactive T cells, myeloid cells and resident microglial 
cells are obligatory requirements for induction of CNS 
pathogenesis of MS. As the major components of the 
innate immune system, microglia and monocyte-derived 
macrophages constitute the first-line barrier of CNS. 
Microglia, which originate from the yolk sac and migrate 
into the CNS during early embryogenesis and acquire 
properties like production of cytokines and chemokines, 
phagocytosis, and antigen presentation [5, 6], are 
exquisitely alert to brain injury and disease [7]. Microglia 
are regarded as liaisons between the immune system and 
CNS, and participate in the regulation of inflammation 
in MS [8]. The process of microglia activation starts 
early in the pathological process of EAE, before the 
entry of peripheral monocyte/macrophage into the CNS 
and appearance of clinical symptoms [8, 9]. Monocyte-
derived macrophages which are indistinguishable from 
microglia at the level of morphology and surface markers, 
have been proved to be associated with EAE exacerbation. 
Elimination of macrophages by means of silica dust or 
liposomes containing dichloromethylene diphosphonate 
remarkably attenuates the clinical signs of EAE [10-
12]. Activated microglia and macrophages, which are 
hallmarks of neuroinflammation, may contribute to CNS 
damage and chronic neurodegeneration through the release 
of harmful cytokines and chemokines, enhancement of 
antigen presentation via upregulation of MHC class II 
molecules, etc [13]. As the core of the adaptive immunity, 
naive CD4+ T cells display a high degree of plasticity 
and the ability to differentiate into effector (such as Th1 
and Th17) and suppressor (such as Treg) sublineages in 
response to various developmental and environmental 
stimuli [14]. Th1 and Th17 cells have been widely 
recognized as central players in the pathogenesis of MS, 
while Tregs are essential in the fine-tune of immune 
activation and confer protection against MS.
Decitabine (5-Aza-2’-deoxycytidine), a FDA-
approved hypomethylating agent, is a chemical analogue 
of cytidine and can incorporate into replicating DNA, 
where it irreversibly inactivates DNMT1 and inhibits 
DNA methylation. At present, decitabine has been 
successfully used to treat myelodysplastic syndrome 
(MDS) through inhibiting cell proliferation by blocking 
DNA synthesis and promoting cell differentiation via 
inducing hypomethylation [15]. More recently, increasing 
evidence showed that decitabine could induce genetically 
and functionally Tregs through Foxp3 demethylation, 
and prevent the occurrence of autoimmune diseases [16-
19]. Two recent studies suggested that decitabine could 
increase the percentage and number of Tregs in EAE mice 
at low dosage (0.15 mg/kg/d), which was thought to be 
essential to protect mice from EAE [20, 21]. However, 
in the treatment of MDS decitabine displays a dual 
mechanism of action depending on dose. Lower dose is 
associated with demethylating activity through promoting 
cell differentiation and expression of tumor suppressor 
genes, while higher dose is cytotoxic by inhibiting cell 
proliferation through trapping DNA methyltransferase 
and blocking DNA synthesis [22]. To further explore the 
immnuo-regulatory effect of decitabine, we attempted 
to increase the dosage of decitabine in EAE and cardiac 
transplantation models, and the mechanism involved was 
also studied.
RESULTS
Decitabine protects mice from MOG-induced 
EAE and inhibits the proinflammatory response 
of CNS
To explore the potential therapeutic effects of 
decitabine on MOG-induced-EAE, peptide MOG35-55-
immunized C57BL/6 mice were treated with decitabine 
(0.25 mg/kg) for 2 consecutive weeks (from day 3 to day 
16 after immunization as preventive protocol or from day 
10 to day 23 as a treatment protocol). Decitabine showed 
potently preventive as well as therapeutic effects on EAE, 
in particular, it completely prevented the onset of EAE 
(Figure 1A, 1C). All mice well tolerated the relatively 
higher dose of decitabine treatment, because there was no 
change in behavior or fur appearance, and body weight 
gain was observed in EAE mice treated with decitabine 
using the preventive protocol (Supplementary Figure 1). 
Consistent with the clinical results, decitabine treated EAE 
mice exhibited much less inflammatory cell infiltration 
and fewer demyelination of spinal cord compared with 
vehicle-treated mice upon pathological examination 
(Figure 1B, 1D). The level of peripheral blood cells could 
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provide information about the presence of inflammation 
induced by infection, autoimmune diseases or allergy. 
Our study suggested that white blood cells, particularly 
lymphocyte subclasses, were lower in decitabine treated 
EAE mice with the treatment protocol as compared with 
the vehicle group (Supplementary Table 1). These results 
supported that decitabine was readily effective in the 
prevention and treatment of EAE in mice.
Ex-vivo data showed that decitabine-treated EAE 
mice were found to have lower frequencies of CNS-
infiltrating inflammatory T cells (CD4+CD45hi and 
CD8+CD45hi), macrophages and activated resident 
microglial cells (CD11b+CD45hi) (Figure 2A). During 
the course of EAE, activated microglia upregulated 
surface expression of CD45 and MHC class II [5]. Along 
this line, decitabine-treated EAE mice showed lower 
expression of MHC class II presented by percentage and 
mean fluorescence intensity (MFI) as compared with the 
vehicle group (Figure 2B, 2C), indicating that decitabine 
could inhibit microglia activation. It is known that 
proinflammatory cytokines and chemokines play crucial 
roles in inflammation and immune cell recruitment. 
Notably, we found that decitabine significantly reduced the 
expression of IL-1, TNF-α, iNOS, which readily caused 
CNS damage per se, as well as a panel of inflammatory 
cytokines and chemokines like CXCL10, CCL2, CCL3, 
CCL4, CCL5, CCL17, CCL22, IL-6, IL-12 and IL-
23, which were associated with T cell recruitment and 
differentiation (Figure 2D, 2E, 2F). These data collectively 
indicated that decitabine downregulated the expression 
Figure 1: Systemic administration of decitabine is exquisitely protective against EAE. Clinical scores of EAE mice received 
either vehicle or decitabine (0.25 mg/kg/day, intraperitoneal injection) treatment for 14 days with the preventive (A) or treatment (C) 
protocols (n=5 mice per group). Data were expressed as mean±S.E.M. Spinal cord sections were stained with H&E or LFB at day 18 for 
prevention protocol (B) or day 30 for treatment protocol (D) after immunization (original magnification, ×40). *P < 0.05.
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Figure 2: Decitabine inhibits proinflammatory response of CNS in EAE mice. CNS (brain and spinal cord) mononuclear cells 
from EAE mice treated with vehicle or decitabine at day18 after immunization were assessed by flow cytometry (A). The expression of 
MHC-II on the CD11b+ population was analyzed. Results were presented as representative plot (B), and histogram with MFI level (C). 
Quantification of mRNA expression of proinflammatory cytokines and chemokines in spinal cords of EAE mice treated with vehicle or 
decitabine (n=5 mice per group) at day 18 after immunization (D, E, F). Data (C, D, E, F) were expressed as mean±S.E.M. *P < 0.05, **P 
< 0.01.
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of key mediators related to CNS inflammation, leading 
to decreased inflammatory infiltration of CNS in the 
pathogenesis of EAE.
Decitabine inhibits allograft rejection and T cell 
allo-immunity in mouse cardiac transplantation
In order to test whether decitabine plays a similarly 
protective role in other immune-related models, we 
performed mouse cardiac transplantation across the 
MHC barrier (BALB/c→B6). Those recipient mice 
were treated with either decitabine (0.25 or 0.5 mg/kg/d) 
or vehicle for 14 consecutive days starting from post-
operative day 1. We found that decitabine (0.25 mg/kg/d) 
significantly prolonged allograft survival in comparison to 
that of the vehicle-treated group (MST= 21.8 vs. 8.7 days, 
p=0.000). More importantly, further increase of decitabine 
dose (0.5 mg/kg/d) could induce permanent allograft 
survival (MST= 100 vs. 8.7 days, p=0.000) (Figure 3A). 
To further evaluate the potency of the recipient-anti-donor 
immune response, we used enzyme-linked immunosorbent 
spot (ELISPOT) assays to quantify donor-specific IFN-γ 
–producing cells in the recipient spleen. We found 
that decitabine-treated recipients using either regimen 
(0.25 or 0.50 mg/kg/d) had obviously fewer donor-
responsive T cells than vehicle-treated control animals 
(Figure 3B), suggesting that decitabine exerted potent 
immunosuppressive effect in allogeneic immune response.
Decitabine regulates T cell differentiation
Since T cell subsets are well-known players that 
orchestrate the pathogenesis of CNS inflammation in 
EAE mice and MS patients, we next examined whether 
decitabine could modulate T cell differentiation. We first 
isolated splenocytes from vehicle- or decitabine-treated 
EAE mice, and analyzed the changes of CD4+ T cell 
subsets. The percentages and absolute numbers of Th1 
Figure 3: Decitabine inhibits cardiac allograft rejection and donor-specific T cell response. (A) Kaplan-Meier survival 
analysis of cardiac allografts with or without decitabine treatment (0.25 or 0.5 mg/kg/day, intraperitoneal injection). (B) Allogeneic T cell 
immunity in cardiac transplantation mice treated with vehicle or decitabine was evaluated by monitoring the alloantigen-specific IFN-γ 
production via ELISPOT assay. Data (A, B) were expressed as mean±S.E.M. ***P < 0.001.
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and Th17 cells were markedly decreased upon decitabine 
treatment (Figure 4A, 4B, Supplementary Figure 2), 
consistent with lower production of proinflammatory 
cytokines characteristic of EAE, including IFN-γ, IL-17, 
and TNF-α (Figure 4C). Unexpectedly, the percentage 
of Foxp3+ Tregs was not significantly affected, and even 
the absolute number was decreased by our decitabine 
treatment protocol (Figure 4D, 4E, Supplementary 
Figure 2). To further confirm the effect of decitabine on 
the differentiation of T cells, we adopted in vitro cell 
differentiation models and found that differentiation 
of naïve CD4+ T cells into Th1 and Th17 cells was 
significantly suppressed in the presence of 1 μM 
decitabine under Th1 and Th17 polarizing conditions, 
respectively (Figure 4F), which was in agreement with 
the in vivo results. However, the expression of Foxp3 was 
significantly increased in the presence of 1 μM decitabine 
compared with control (Figure 4F), though in vivo studies 
showed no obvious change.
Decitabine inhibits T cell proliferation in vitro 
and ex-vivo
Despite the multifaceted roles of decitabine on 
innate and adaptive immune responses, surprisingly few 
studies have shed light on its influence on effector T cell 
activation, which is the cornerstone of the pathogenesis in 
both auto- and allo-immunities. Therefore, we attempted 
to explore the effect of decitabine on T cell proliferation 
and the underlying mechanism. Splenocytes from wild-
type mice were stimulated with anti-CD3/anti-CD28 
monoclonal antibodies (mAbs) in the presence of 
decitabine at various concentrations. We observed a strong 
dose-dependent inhibition of the proliferation in both 
CD4+ and CD8+ subsets, as judged by the CFSE profile 
(Figure 5A). This inhibitory effect was not attributed to 
induction of cell apoptosis (Supplementary Figure 3). To 
further determine whether decitabine could inhibit antigen-
specific T cell response, we investigated the response of 
encephalitogenic T cells to MOG peptide ex vivo using 
[3H] thymidine incorporation assay. The proliferation of 
encephalitogenic T cells in decitabine-treated mice was 
much weaker than the vehicle-treated group upon MOG 
peptide re-stimulation in vitro (Figure 5B).
The inhibition of T cell proliferation by 
decitabine is associated with increased 
expression of several cell cycle inhibitors
To further explore the mechanism through which 
decitabine inhibited the proliferation of T cells, the 
expression of a panel of cell cycle–related proteins which 
are known to be involved in the regulation of lymphocyte 
proliferation [24, 25] were examined. Compared with 
vehicle-treated CD4+ naïve counterparts, quantitative PCR 
revealed significantly increased expression of several key 
cell cycle inhibitors (p15, p16, p21 but not p27) in those 
naïve T cells underwent decitabine treatment (Figure 6A).
In addition to the cyclin dependent kinase inhibitors, 
other cell cycle-related proteins (such as cyclin-dependent 
kinases and cyclins) also control cell proliferation via 
regulating cycle progression [26]. Compared with vehicle 
controls, there was significantly reduced expression of 
Cyclin A, phosphorylated retinoblastoma protein(p-Rb) 
and Cyclin B1 (Figure 6B, 6C) in decitabine-treated 
T cells, while no difference in the expression of Cyclin D1, 
cyclin-dependent kinase 2 (Cdk2) and cyclin-dependent 
kinase 6 (Cdk6) after decitabine treatment was observed 
(Figure 6B, 6C).
The inhibition of T cell proliferation by 
decitabine is associated with increased 
expression of TET2
The ten-eleven-translocation (TET) family 
proteins including TET1, TET2 and TET3 belong 
to the α-ketoglutarate and Fe2+-dependent enzymes, 
which can alter the methylation status of DNA by 
catalyzing the conversion of 5-methyl-cytosine (5-mC) 
to 5-hydroxymethyl-cytosine (5-hmC) and promote DNA 
demethylation [27]. TET2 is the most abundant TET 
protein in hematopoietic cells [28]. Decitabine is a well-
recognized DNMT inhibitor, however, whether it also 
has an impact on TET family proteins remains obscure. 
RT-qPCR showed that in CD4+ naïve T cells stimulated 
with anti-CD3 and anti-CD28 antibodies, decitabine 
could significantly upregulate the expression of TET2 
and TET3, but reduce that of TET1 (Figure 6D). To study 
the functions of TET proteins, we knocked-down TET1, 
TET2, and TET3. Interestingly, knockdown of TET2 
reduced the expression of p15, p16 and p21 in T cells, 
but had little impact on that of p27 (Figure 6E). More 
importantly, while decitabine treatment greatly boosted 
the expression of p15, p16 and p21, such effect was 
significantly diminished when TET2 was knocked down, 
suggesting this effect is partially dependent on TET2. In 
contrast, no obvious changes of these cell cycle inhibitors 
could be observed when TET1 or TET3 was knocked-
down in either vehicle-treated or decitabine-treated CD4+ 
naïve T cell (Supplementary Figure 4A, 4B). To confirm 
the direct effects of TET2 on the gene transcription of 
p15, p16, p21 and p27, we performed ChIP assay using 
TET2 antibody. Our results showed that in naïve T cells, 
TET2 was enriched in promoters of p15, p16 and p21 
genes, but not in p27 (Figure 6F). We further investigated 
the effect of TET proteins on the proliferation of CD4+ 
naïve T cells. Consistent with the aforementioned results, 
knocking-down TET2 clearly promoted the proliferation 
of CD4+ naïve T cells either in decitabine or vehicle-
treated group (Figure 6G), while knockdown of TET1 or 
TET3 had minimal impact on CD4+ T cell proliferation 
(Supplementary Figure 4C, 4D). Taken together, our data 
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Figure 4: Decitabine modulates T cell differentiation in vivo and in vitro. Splenocytes were harvested from EAE mice treated 
with vehicle or decitabine at day18 after immunization. The frequency of Th1 and Th17 in splenocytes was analyzed by FACS (A, 
B). Splenocytes were restimulated with MOG35–55 peptide (25 μg/ml), and culture supernatants were collected at 72 h for cytokine 
measurement by ELISA (C). The frequency of Treg population in splenocytes was analyzed by FACS (D, E). The effect of decitabine on 
Th1, Th17, Treg differentiation in vitro was analyzed by FACS (F). Data (B, C, E) were expressed as mean±S.E.M. *P < 0.05, **P < 0.01, 
***P < 0.001.
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revealed that decitabine treatment increased the expression 
of TET2, which regulated the transcription of certain cell 
cycle inhibitors (p15, p16 and p21) and inhibition of CD4+ 
naïve T cell proliferation in vitro.
DISCUSSION
In this work, we proved that the methylation-
modifying drug decitabine could become a promising 
therapeutic strategy in the treatment of MS as well as in 
the prevention of cardiac allograft rejection. However, 
other than previous studies which claimed the protective 
effect by decitabine in EAE was mainly attributed to 
the induction of Tregs, we provided solid evidence 
that multifaceted mechanisms were involved in this 
overwhelmingly immunosuppressive effect by decitabine. 
Decitabine was capable of inhibiting both innate and 
adaptive immunity to hinder the progression of EAE. 
Furthermore, increasing the dosage of decitabine would 
not further increase the proportion and/or absolute number 
of Tregs as expected, instead, the relatively higher dose of 
decitabine had negligible effect on the proportion of Tregs 
in vivo as compared to the vehicle control.
Dysregulation of the innate immune response 
plays a crucial role in the pathogenesis of MS [29]. 
In particular, excessive activation of microglia and 
monocyte-derived macrophages contributes to the 
development and progression of MS. In the current 
study, we found that decitabine significantly suppressed 
the activation of microglia and monocyte-derived 
macrophages, characterized by lower levels of surface 
MHC II expression. It is well-established that activated 
microglia and macrophages produce cytokines and 
chemokines that recruit additional encephalitogenic T 
cells to the CNS and exacerbate CNS damage [30-32]. In 
our study, we found that decitabine significantly inhibited 
Figure 5: Decitabine inhibits naïve T proliferation in vitro and modulated MOG-reactive CD4+T cell response in vivo. 
The effect of decitabine on the proliferation of T cell subsets stimulated with anti-CD3 plus anti-CD28 mAbs at different concentrations 
was examined by CFSE-based assay (A). Splenocytes from EAE mice treated with or without decitabine were restimulated ex vivo with 
indicated concentrations of the MOG35–55 peptide, and cell proliferation was assessed by [3H] thymidine incorporation assay (B). All data 
were expressed as mean±S.E.M. ***P < 0.001.
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Figure 6: The inhibition of decitabine on T cell proliferation is associated with increased expression of several cell 
cycle inhibitors and TET2. Decitabine (10 μM) promoted the mRNA expression of several cell cycle inhibitors (p15, p16, p21, p27) 
upon T cell activation (A). The effect of decitabine (10 μM) on the cell cycle progression of naïve CD4+ T cell stimulated with anti-CD3 
plus anti-CD28 mAbs at different concentrations was analyzed by western blot (B) and real-time PCR (C). Decitabine (10 μM) promoted 
the expression of TET2 and TET3 but reduced TET1 expression in naïve CD4+ T cells stimulated with anti-CD3 plus anti-CD28 mAbs in 
vitro (D). After knocking down the expression of TET2 in naïve CD4+ T cells, these cells were treated with vehicle or decitabine (10 μM). 
The different impacts on the transcriptional level of cell cycle inhibitors (p15, p16, p21, p27) (E) and the rate of cell proliferation (G) were 
shown. (F) ChIP assays of naïve CD4+ T cells, using an anti-TET2 antibody and PCR primers specific for promoters of p15, p16, p21 and 
p27. IgG antibody was used as negative control and input DNA was used as internal control. Data (A, C, D, E, F, G) were expressed as 
mean±S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001.
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the release of chemokines (CCL2, CCL3, CCL4, CCL5, 
CXCL10, CCL17, CCL22) from activated microglia and 
macrophages, which hindered encephalitogenic T cells 
to the CNS and prevented the disease process of EAE. 
Increased expression of IL-12, IL-6, IL-23 in activated 
microglia and macrophages could also direct Th1 and 
Th17 cell differentiation [5, 33]. Our investigation 
revealed that decitabine inhibited the upregulation of these 
cytokines from microglia and macrophages in EAE mice, 
that may be responsible for inhibiting the differentiation of 
Th1 and Th17 cells, decreasing the production of IL-17A, 
IFN-γ from these cells and easing the impairment caused 
by EAE. Apparently, reduced differentiation of Th1 and 
Th17 could also be partially attributed to impaired T cell 
proliferation in the presence of decitabine.
Recent studies demonstrated that mice with 
decitabine treatment were significantly protected against 
EAE through inactivation of DNMT1, thus facilitated 
demethylation of the Foxp3 promoter and induction of 
Treg differentiation [20, 21]. However, we found that 
although decitabine treatment significantly increased 
Foxp3 expression in the in vitro differentiation assay, 
the percentage of Foxp3+ Tregs in spleen or thymus 
showed no obvious changes in vivo (Figure 4D, 4E, and 
Supplementary Figure 5G, 5H). This difference may 
be explained by the dose and duration of decitabine 
administration. The regimen we use in this study was 
0.25 mg/kg for 2 consecutive weeks, while the previous 
studies used 0.15 mg/kg for 10 consecutive days or 0.1 
mg/kg for 22 consecutive days, respectively [20, 21]. 
We hypothesized that increased dose of decitabine 
treatment mainly resulted in the inhibition of T cell 
proliferation, which led to shrinkage of effector T 
cell repertoire. Decitabine not only dose-dependently 
inhibited both CD4+ and CD8+ T cell proliferation in 
vitro, it decreased the size, weight and total cell numbers 
of thymus in EAE mice (Supplementary Figure 5A, 
5B, 5C). Furthermore, by analyzing the composition of 
thymocytes in decitabine-treated EAE mice, we found that 
although decitabine had varying impacts on the percentile 
of cell subsets (Supplementary Figure 5D, 5E), it nearly 
decreased the absolute numbers of all cell populations 
in thymus (Supplementary Figure 5F), including Tregs 
(Supplementary Figure 5G, 5H). Our results were in 
consistent with a previous report using decitabine in the 
treatment of MDS. The major finding was that both high 
and low dose of decitabine could prevent the progress 
of MDS through different mechanisms. While low dose 
decitabine promoted cell differentiation, high dose 
inhibited tumor cell proliferation through blocking DNA 
synthesis [22]. However, in the setting of robust immune 
response such as in our EAE and allo-transplantation 
models, we have clearly shown in our previous studies 
that tipping the balance between the Teff versus Treg 
population was critical to achieve permanent allograft 
survival [34]. Since Teffs proliferate much faster than 
Tregs upon TCR ligation or other stimulation, thereby 
quickly skewing the balance towards the Teff side, it’s 
unlikely that such kind of robust immune response 
can be controlled by even “super-Tregs”, the number 
of Tregs may be more critical in such setting. In fact, 
despite its in vitro effect, decitabine merely increased 
the Treg population in vivo. Therefore, we think the 
such overwhelming effect of decitabine in controlling 
autogeneic or allogeneic immune response is more than 
generating “super-Tregs”. So it’s rational for us to look 
at the Teff population which is most critical player in this 
kind of immune response. Based on the current results, 
we conclude that inhibition of Teff activation may be 
the utmost important mechanism to explain the robust 
therapeutic effect of decitabine in either autogeneic or 
allogeneic immune reactions.
To further explore the mechanism regarding inhibition 
of T cell proliferation by decitabine, we found increased 
transcription of several key cell cycle inhibitors (p15, p16, 
p21) by promoter demethylation, which inhibited cell 
cycle progression of CD4+ naïve T cells and hindered cell 
proliferation. More importantly, we unexpectedly found 
that in addition to its well-known inherent effect of DNMT 
inhibition, decitabine induced expression of several key cell 
cycle inhibitors partially via increased expression of a TET 
family member, TET2, in CD4+ T cells upon activation. 
Further investigation confirmed that the upregulation of 
TET2 rather than TET1 or TET3 inhibited CD4+ T cell 
proliferation in vitro. TET2 has been known to orchestrate 
the regulation of promoter methylation status by converting 
5mc to 5hmc, and function as a tumor suppressor in myeloma 
and lymphoma [35]. The thylcytosine dioxygenase TET2 
could promote DNA demethylation to control the production 
of IFN-γ and IL-17 in autoimmunity [7], and was required to 
resolve inflammation by recruiting HDAC2 and repressing 
transcription of IL-6 through histone deacetylation [36]. A 
recent study also reported 5-azacytidine could induce the 
expression of TET2 and reshape morphology of human 
skin fibroblasts [37]. To our knowledge, this the first time to 
report that decitabine can control TET expression in CD4+ 
T cells and the importance of TET2 in controlling CD4+ T 
cell proliferation. Collectively, our results suggest decitabine 
promoted target gene promoter demethylation not only by 
inhibition of DNMT activity, but via boosting the expression 
of DNA demethylase TET family member in certain cell 
types. Interestingly, we identified that knockdown of TET2 
could upregulate the expression of p15, p16 and p21, but had 
minimal effect on that of p27, suggestive of the selectivity of 
TET2 in controlling gene transcription.
In summary, our study reveals decitabine can be a 
highly effective approach in the prevention and treatment 
of EAE, as well as transplant rejection. It also provides 
a novel mechanism of decitabine on immune regulation 
which may help to develop potentially innovative 





Male C57BL/6 and Balb/c mice aged 6–8 weeks 
were purchased from the Shanghai SLAC Laboratory 
Animal Co., Ltd (Shanghai, China). The mice were housed 
in specific pathogen-free conditions and humanely cared 
according to the criteria outlined in the National Guideline 
for the Care and Use of Laboratory Animals. All animal 
protocols were approved by the Institutional Animal 
Care and Use Committee of Zhejiang Provincial People’s 
Hospital.
EAE induction in C57BL/6 mice and decitabine 
treatment
EAE was induced by subcutaneous injection of 
300 μg myelin oligodendrocyte glycoprotein (MOG 
35–55) peptide (Sigma, St Louis, MO, USA) emulsified 
in complete Freud’s adjuvant containing 5 mg/ml heat-
killed mycobacterium tuberculosis H37Ra (Sigma, St 
Louis, MO, USA). On the day of immunization and 48 h 
later, mice were administered intravenously with 200 ng 
pertussis toxin (List Biological Laboratories, Campbell, 
CA, USA) in 200 μl of PBS.
Mice received daily intraperitoneal administration 
of either decitabine (Selleck, USA) (0.25 mg/kg/day) 
or the same volume of vehicle control for a total of two 
weeks, starting from day 3 (prevention protocol) or 10 
(treatment protocol) after immunization. Mice were 
observed daily and assessed disease severity according 
to the following standard criteria [7]: 0 = no obvious 
clinical sign, 1 = limp tail, 2 = hind limb weakness, 
3= complete paralysis of two hind limbs, 4= paraplegia 
with fore limb weakness or paralysis, 5= moribund or 
dead.
Isolation of CNS infiltrating mononuclear cells 
from EAE mice
To isolate CNS infiltrating cells from EAE 
mice treated with vehicle or decitabine at day18 after 
immunization, mice received cardiac perfusion with 50 
ml PBS to remove cells from blood vessels under deep 
anesthesia with 1% pentobarbital sodium. The brain and 
spinal cord were removed and cut into small pieces in a 
70 μm cell strainer placed on a 50 ml tube. The single cell 
suspension was centrifuged at 390 g for 10 min, and then 
the cell pellet was resuspended in 10 ml of 37% Percoll 
and overlaid on 5 ml of 70% Percoll. The sample was 
centrifuged at 390 g for 20 min at room temperature. After 
centrifugation, the interphase containing mononuclear 
cells was carefully collected and washed with PBS for 
further analysis.
Cardiac transplantation and decitabine 
treatment
Cardiac transplantation was performed using 
microsurgical techniques. Briefly, the donor(Balb/c) 
ascending aorta was sutured to the recipient(C57BL/6) 
abdominal aorta in an end-to-side fashion using 10-0 
continuous sutures (USSC), and the pulmonary artery to 
the recipient inferior vena cava (IVC) in the same manner. 
Prevention of cardiac allograft rejection was induced by 
intraperitoneal administration of decitabine (0.25 or 0.50 
mg/kg/day) or vehicle control for 14 days from day 1 after 
transplantation. Allograft survival time was determined 
by daily trans-abdominal palpation of heart beating and 
confirmed by histological examination.
Histology
Lumbar spinal cords from decitabine- and vehicle- 
treated EAE mice at day 18 for prevention protocol 
and day 30 for treatment protocol after immunization 
were embedded in paraffin after being fixed in 4% 
paraformaldehyde (Sigma, St Louis, MO, USA). 
Samples were then cut into 10 μm slices and stained with 
conventional hematoxylin and eosin (H&E) to assess 
infiltration of inflammatory cell or stained with Luxol fast 
blue (Sigma-Aldrich, St Louis, MO, USA) to evaluate 
demyelination.
Enzyme-linked immunosorbent spot (ELISPOT) 
assay
ELISPOT (e-Bioscience, San Diego, CA) assay was 
performed according to manufacturer’s protocol to assess 
donor-specific T cell immunity in cardiac transplantation 
recipient mice by analyzing the production of IFN-γ after 
rechallenging with allogeneic or syngeneic antigens. 
Briefly, 96-well plates were coated with capture anti-IFN-γ 
antibody overnight, 1×105 recipient splenocytes were 
added to the wells in 200 ml completed RPMI medium. 
They were stimulated with either irradiated donor bone 
marrow–derived dendritic cells, or recipient bone marrow–
derived dendritic cells as syngeneic controls. No stimulator 
was added in the negative controls [38]. After incubation 
(37°C, 5% CO2) for 24 h, biotinylated detection antibody, 
avidin-horseradish peroxidase and substrate solution were 
added sequentially followed by incubation and washing 
after each step. Finally, the spots development in each well 
was read by an automated Immunospot Analyzer (Cellular 
Technology, Cleveland, OH).
Knockdown of TET1, TET2 and TET3 in naïve 
T cells via shRNA
ShRNAs for knockdown of TET1, TET2, TET3 
and GFP-control were constructed into pLvx-shRNA2 
Oncotarget56813www.impactjournals.com/oncotarget
(Clontech, Takara) digested with BamHI and EcoRI, and 
tranfected to HEK293T cells with packaging plasmids 
(pspax2, pMD2G) using Lipofectamine® 3000 (Thermo, 
USA). Supernatant was harvested at 24 h and 72 h 
after transfection and infected anti-CD3ε/CD28 mAb-
stimulated naïve T cells. Transfected T cells were then 
treated with decitabine (10 μM) or vehicle for 96 h. Cells 
were harvested for real-time PCR to analyze the efficiency 
of knockdown. ShRNA sequences were detailed in 
Supplementary Table 2.
Proliferation and differentiation of naive T cells 
in vitro
Naive T cells were isolated using CD4+CD62Lhigh 
T Cell Isolation Kit (Miltenyi Biotech) from spleen and 
lymph nodes. Purified CD4+CD62Lhigh T cells (1.5×105 
cells/well) were cultured in the presence of anti-CD3ε 
mAb (2 μg/ml) with or without anti-CD28 mAb (2μg/ml) 
in complete RPMI medium. Different concentrations of 
decitabine (1 μM, 5 μM, 10 μM) or vehicle were added 
at the beginning of T cell proliferation. For differentiation 
of naïve T cells, IL-12 (10 ng/ml), IL-2 (10 ng/ml), anti-
IL-4 (10 μg/ml) and either decitabine or vehicle were 
added to the culture medium in Th1-skewing conditions. 
In Th17-skewing conditions, IL-6 (50 ng/ml), IL-23 (20 
ng/ml), TGF-β (3 ng/ml), anti-IL-4 (10 μg/ml), anti-IFN-γ 
(10 μg/ml), and either decitabine or vehicle were added 
to the culture medium. 4 days later, cells were harvested 
for FACS, real-time PCR, CFSE or WST-8 (Biotool, 
USA) assays to evaluate the effect of decitabine on the 
proliferation and differentiation of naive T cells.
Flow cytometry
Cell surface staining (CD4, CD8, MHC-II, 
CD44, CD69, CD62L) (eBioscience) was performed at 
4°C for 30 min in the dark. For intracellular cytokine 
staining (IFN-γ and IL-17A) or intranuclear staining 
for Foxp3 we first labeled cells with surface markers, 
fixed, permeabilized, and then stained them with IFN-γ, 
IL-17A or Foxp3 monoclonal antibody (eBioscience). 
Stained cells were analyzed by FACS Canto II flow 
cytometer with Diva software (BD Biosciences), 
data were processed using FlowJo software (Treestar, 
Ashland, OR).
Chromatin immunoprecipitation (ChIP) assays 
and quantitative real-time PCR
ChIP assays were performed using TET2 
(Diagenode), IgG antibody as control (Cell signaling 
technology), and iDeal ChIP-seq Kit for Transcription 
Factors (Diagenode) with primer pairs specific for the 
promoters of p15, p16, p21 and p27 genes. Primer 
sequences are available upon request. For quantitative 
real-time PCR, total RNA was extracted from CD4+ naïve 
T cells using TRIzol (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions, and reverse 
transcribed to cDNA with a PrimeScriptTM RT reagent kit 
(Takara). Quantitative PCR was performed using SYBR 
Green master mix (Takara) and Applied Biosystems 
ViiA™ 7 Real-time PCR system. Primer pairs were 
detailed in Supplementary Table 3.
Statistical analysis
Data from different groups were compared using the 
student’s t-test, except for the clinical scores of EAE mice, 
which was performed with the Mann-Whitney U test. P 
value < 0.05 was considered statistically significant.
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